2.

疗效评价

Response of all patients

Patients	Response			PFS2 (month)
	PR	SD	PD
TKIs: tyrosine kinase inhibitors; PR: partial response; SD: stable disease; PD: progressive disease. CNS metastasis vs No-CNS metastasis, P=0.017. PFS: progression free survival.
Total	11 (24%)	23 (51%)	11 (24%)	5.9
CNS metastasis (23)	8 (35%)	12 (52%)	3 (13%)	7.6
No-CNS metastasis (22)	3 (14%)	11 (50%)	8 (36%)	4.1
Continuation-EGFR-TKI+Local therapy (29)	6 (21%)	16 (55%)	7 (24%)	5.4
Switch- EGFR-TKI+Local therapy (16)	5 (31%)	8 (50%)	3 (19%)	6.1